33161784|t|Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system.
33161784|a|Introduction: Metformin is currently first line therapy for type 2 diabetes (T2D). The mechanism of action of metformin involves activation of AMP-activated protein kinase (AMPK) to enhance mitochondrial function (for example, biogenesis, refurbishment and dynamics) and autophagy. Many neurodegenerative diseases of the central and peripheral nervous systems arise from metabolic failure and toxic protein aggregation where activated AMPK could prove protective. Areas covered: The authors review literature on metformin treatment in Parkinson's disease, Huntington's disease and other neurological diseases of the CNS along with neuroprotective effects of AMPK activation and suppression of the mammalian target of rapamycin (mTOR) pathway on peripheral neuropathy and neuropathic pain. The authors compare the efficacy of metformin with the actions of resveratrol. Expert opinion: Metformin, through activation of AMPK and autophagy, can enhance neuronal bioenergetics, promote nerve repair and reduce toxic protein aggregates in neurological diseases. A long history of safe use in humans should encourage development of metformin and other AMPK activators in preclinical and clinical research. Future studies in animal models of neurological disease should strive to further dissect in a mechanistic manner the pathways downstream from metformin-dependent AMPK activation, and to further investigate mTOR dependent and independent signaling pathways driving neuroprotection.
33161784	0	9	Metformin	Chemical	MESH:D008687
33161784	41	61	neurological disease	Disease	MESH:D020271
33161784	74	78	AMPK	Gene	5564
33161784	123	132	Metformin	Chemical	MESH:D008687
33161784	169	184	type 2 diabetes	Disease	MESH:D003924
33161784	186	189	T2D	Disease	MESH:D003924
33161784	219	228	metformin	Chemical	MESH:D008687
33161784	252	280	AMP-activated protein kinase	Gene	5564
33161784	282	286	AMPK	Gene	5564
33161784	396	422	neurodegenerative diseases	Disease	MESH:D019636
33161784	480	497	metabolic failure	Disease	MESH:D051437
33161784	544	548	AMPK	Gene	5564
33161784	621	630	metformin	Chemical	MESH:D008687
33161784	644	663	Parkinson's disease	Disease	MESH:D010300
33161784	665	685	Huntington's disease	Disease	MESH:D006816
33161784	696	717	neurological diseases	Disease	MESH:D020271
33161784	767	771	AMPK	Gene	5564
33161784	806	835	mammalian target of rapamycin	Gene	2475
33161784	837	841	mTOR	Gene	2475
33161784	854	875	peripheral neuropathy	Disease	MESH:D010523
33161784	880	896	neuropathic pain	Disease	MESH:D009437
33161784	934	943	metformin	Chemical	MESH:D008687
33161784	964	975	resveratrol	Chemical	MESH:D000077185
33161784	993	1002	Metformin	Chemical	MESH:D008687
33161784	1026	1030	AMPK	Gene	5564
33161784	1142	1163	neurological diseases	Disease	MESH:D020271
33161784	1195	1201	humans	Species	9606
33161784	1234	1243	metformin	Chemical	MESH:D008687
33161784	1254	1258	AMPK	Gene	5564
33161784	1343	1363	neurological disease	Disease	MESH:D020271
33161784	1450	1459	metformin	Chemical	MESH:D008687
33161784	1470	1474	AMPK	Gene	5564
33161784	1514	1518	mTOR	Gene	2475
33161784	Positive_Correlation	MESH:D010523	5564
33161784	Association	MESH:D010523	2475
33161784	Negative_Correlation	MESH:D008687	MESH:D020271
33161784	Association	MESH:D020271	5564
33161784	Negative_Correlation	MESH:D008687	MESH:D006816
33161784	Positive_Correlation	MESH:D008687	5564
33161784	Association	MESH:D019636	5564
33161784	Negative_Correlation	MESH:D008687	MESH:D003924
33161784	Association	MESH:D009437	5564
33161784	Association	MESH:D009437	2475
33161784	Negative_Correlation	MESH:D008687	MESH:D010300

